Study summary · research use only
[Immunomodulating activity of thymogen in acute pancreatitis]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human study evaluated immune system parameters in 48 people diagnosed with acute pancreatitis compared with 36 healthy donors. The authors report that patients with acute pancreatitis showed declines in immune parameters, particularly in T-cell measures. Adding thymogen to treatment at a dose of 0.5-0.8 mg over the treatment course was associated with changes in immune measures and with clinical changes the authors describe as positive, including resolution of the T-cell deficiency observed in these patients. Species: human.
Abstract
Immunity system parameters were explored at 48 persons with diagnosis of acute pancreatitis (AP) and at 36 practically healthy persons (donors). At AP diseased were found declinations in immunity system especially at the side of immunity T-cell link. Including of tymogen in complex treatment at the dose 0.5-0.8 mg for the treatment course at AP diseased was having immune correcting action and leadind to positive dynamics of clinical changes. It was observed elimination of T-cell immune deficiency at AP diseased.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.